Diabetes favors soluble forms of amyloid beta, which are particularly toxic and damaging to neuronal tissue. This scientific discovery is related to this disease Alzheimer’sWith Professor of the Department of Physiology of the UGR Juan José Ramos Rodríguez, according to a study in which researchers from the University of Cádiz Mónica García Aloza and María Vargas Soria participate.
The description of the amyloid beta peptide deposition process in a combined model of Alzheimer’s disease and diabetes provides a new therapeutic target to target to slow or stop the progression of the disease. Madness, It is one of the main ways to explore the future.
In recent years, diabetes and prediabetes have been recognized as a risk factor for dementia, but the mechanisms mediating this association are not fully known. This work highlights one of the ways in which type 2 diabetes mellitus or its earlier stage, prediabetes, contribute to cognitive decline and accelerate the progression of Alzheimer’s disease. Study describes a new development of pathology beta amyloid in Alzheimer’s patients Those who also have prediabetes or type 2 diabetes.
The novelty of the obtained results is based on the detection of a different progression of amyloid beta pathology when only Alzheimer’s disease is encountered and a second development when this dementia is accompanied by type 2 diabetes or prediabetes. In the combined model, there is an excess accumulation of beta amyloid peptide at the vascular level, which is known as beta-amyloid angiopathy. Furthermore, diabetes favors soluble forms of the amyloid beta peptide, which are the most toxic and damaging to neuronal tissue. Said modification of beta-amyloid pathology leads to increased oxidative stress at the neuronal and vascular levels. lets break it all down blood vessels in the brain and potentiates the neuronal death typical of Alzheimer’s disease.
The research has developed in live animals thanks to a sophisticated multiphoton microscopy technique, which allows the monitoring of a single animal and a brain pathology over time. “This reduces the number of animals needed in research, without doubt a huge advantage over more rudimentary techniques, which triple the number of animals needed to conduct a similar study,” explains the UGR professor. “ juan jose ramos, ‘In vivo’ multiphoton microscopy is a technique within reach of some laboratories, capable of offering data and images that cannot be achieved with other techniques. “The next question we ask ourselves is: By controlling diabetes pathology, can we control or reduce the progression of beta-amyloid pathology and its consequences?” Researchers from the University of Granada have concluded.